KalshiFinancials
FDA decision: Ifinatamab Deruxtecan by Daiichi Sankyo (in 2026)
FDA decision on Ifinatamab Deruxtecan in 2026
Ends Jan 1, 2027
Bet NowDisclosure
18+ only. Event contracts carry significant risk and are not suitable for everyone, you can lose the entire amount you commit. Not available in all jurisdictions; restrictions and eligibility requirements apply.
Probability
- a full approval or an accelerated approval1.1K VOL.Yes 81%No 19%81¢
Rules Summary
If the FDA's decision on Ifinatamab Deruxtecan by Daiichi Sankyo in 2026 is a full approval or an accelerated approval, the market resolves to Yes.
Timeline and Payout
- Opened
- Jun 17, 2026, 9:00 PM
- Closes
- Jan 1, 2027, 4:59 AM
- Pays out
- 0.5 hours after close
Series KXIFINATAMAB · Event KXIFINATAMAB-27 · Market KXIFINATAMAB-27-Y